Atlas Trials

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Clinical trial NCT03465787 · COMPLETED

Trial details

NCT number
NCT03465787
Sponsor
Bukwang Pharmaceutical
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2018-04-09
Primary completion
2022-10-26
Enrollment
210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.